CANF — Can Fite Biopharma Share News
0.000.00%
Last trade - 00:00- $4.92m
- $1.93m
- $0.41m
Brief: Can-Fite's NASH Patents Granted And Allowed In Japan, Hong Kong, And Mexico
Brief: Can Fite Biopharma Ltd Says Positive Data From Phase IIA Can-Fite Nash Study Published In Leading Peer Reviewed Scientific Journal
Brief: Can-Fite Completes Patient Enrollment In Phase Iii Psoriasis Study
Brief: Can Fite Biopharma Ltd Files For Potential Sale Of Up To 160.5 Mln Ordinary Shares By Selling Stockholders
Brief: Can-Fite Biopharma Says Entered Into Agreement For Purchase & Sale Of 5 Mln ADSs
Brief: Yossi Borenstein, CEO And Founder Of Shizim Group, Has Been Elected To Can-Fite Board
Brief: Can-Fite Gears Up To Initiate Pivotal Phase III Liver Cancer Study
Can-Fite BioPharma gains on deal to develop lead drug for arthritis in pets
Signs Agreement With Vetbiolix For Development Of Piclidenoson For Pets
Brief: Can-Fite Receives Notice Of Patent Allowance In China For NASH Treatment
Brief: Can-Fite Biopharma Says To Initiate Phase Iib Nash Study With Its Drug Candidate Namodenoson
Brief: Can-Fite Reports Qtrly Loss Per Share $0.00
Brief: Can-Fite’S Phase 3 Psoriasis Study Achieves 75% Enrollment, Results Expected Q4 2021
Brief: Can-Fite Initiates Preclinical Studies Required By FDA And EMA For Registration Of Its Two Lead Drug Candidates
U.S. STOCKS ON THE MOVE-Alphabet Inc, AMC Entertainment, oil stocks, cruise stocks
U.S. STOCKS ON THE MOVE-AeroCentury, Molecular Templates, Tesla Inc and Xcel Brands
U.S. STOCKS ON THE MOVE-Chembio Diagnostics, Gogo Inc, Bio-Path Holdings, Leaf Group
Can-Fite BioPharma: Rises on positive preclinical data for cannabis compound
Brief: Can Fite Biopharma Says Completed Pre-Clinical Studies Demonstrating Cbd Rich T3/C15 Cannabis Fraction Induces Inhibition Of Liver Cancer Cell Growth